Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition

Concurrent regulation of the transcription factors Nrf2 and ATF4 mediates the enhancement of glutathione levels by the flavonoid fisetin

(2013) Jennifer L. Ehren et al.   BIOCHEMICAL PHARMACOLOGY

Nrf2 activation is associated with Z-DNA formation in the human HO-1 promoter

(2013) Atsushi Maruyama et al.   NUCLEIC ACIDS RESEARCH

Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells

(2013) Wei Qi et al.   PLoS One

The Cystine/Glutamate Antiporter System xc− in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities

(2012) Jan Lewerenz et al.   ANTIOXIDANTS & REDOX SIGNALING

Glutathione synthesis

(2012) Shelly C. Lu   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells

(2012) Zhi-Hong Zong et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Activating transcription factor 4 increases chemotherapeutics resistance of human hepatocellular carcinoma

(2012) Zhuhong Zhang et al.   CANCER BIOLOGY & THERAPY

Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming

(2012) Yoichiro Mitsuishi et al.   CANCER CELL

Targeting the ATF4 pathway in cancer therapy

(2012) Dean C Singleton et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Increased xCT Expression Correlates With Tumor Invasion and Outcome in Patients With Glioblastomas

(2012) Satoru Takeuchi et al.   NEUROSURGERY

Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma

(2012) HIROKI KINOSHITA et al.   ONCOLOGY REPORTS

The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism

(2012) Yoichiro Mitsuishi et al.   Frontiers in Oncology

The Cystine/Cysteine Cycle and GSH Are Independent and Crucial Antioxidant Systems in Malignant Melanoma Cells and Represent Druggable Targets

(2011) Roberta Venè et al.   ANTIOXIDANTS & REDOX SIGNALING

CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth

(2011) Takatsugu Ishimoto et al.   CANCER CELL

Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma

(2011) Weijie Guo et al.   CANCER LETTERS

Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression

(2011) J Lewerenz et al.   CELL DEATH AND DIFFERENTIATION

Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution

(2011) Keiko Taguchi et al.   GENES TO CELLS

Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application

(2011) Xiaoping Yang et al.   International Braz J Urol

Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview

(2010) Ken Itoh et al.   ANTIOXIDANTS & REDOX SIGNALING

Cancer cell sensitivity to bortezomib is associated with survivin and p53 status but not cancer cell types

(2010) Xiang Linf et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Bortezomib

(2009) Monique P. Curran et al.   DRUGS

ATF4-dependent transcription mediates signaling of amino acid limitation

(2009) Michael S. Kilberg et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

The present and future burden of urinary bladder cancer in the world

(2009) Martine Ploeg et al.   WORLD JOURNAL OF UROLOGY

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

The xc− cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases

(2008) Maisie Lo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway

(2008) R-S Chen et al.   ONCOGENE

Activating transcription factor 4

(2007) Kurosh Ameri et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY